197 related articles for article (PubMed ID: 31636783)
1. Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice.
Iitake C; Iitake K
J Clin Med Res; 2019 Oct; 11(10):690-695. PubMed ID: 31636783
[TBL] [Abstract][Full Text] [Related]
2. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
Ginsberg HN; Hounslow NJ; Senko Y; Suganami H; Bogdanski P; Ceska R; Kalina A; Libis RA; Supryadkina TV; Hovingh GK
Diabetes Care; 2022 Apr; 45(4):898-908. PubMed ID: 35238894
[TBL] [Abstract][Full Text] [Related]
4. Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis.
Yamashita S; Rizzo M; Su TC; Masuda D
Metabolites; 2023 May; 13(5):. PubMed ID: 37233667
[TBL] [Abstract][Full Text] [Related]
5. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
[TBL] [Abstract][Full Text] [Related]
6. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
Iitake C; Masuda D; Koseki M; Yamashita S
Cardiovasc Diabetol; 2020 Nov; 19(1):201. PubMed ID: 33246467
[TBL] [Abstract][Full Text] [Related]
7. A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients.
Yanai H; Katsuyama H; Hakoshima M
Cardiol Res; 2021 Dec; 12(6):358-362. PubMed ID: 34970366
[TBL] [Abstract][Full Text] [Related]
8. Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor α Modulator (SPPARMα) in Japanese Patients with Renal Impairment and Dyslipidemia.
Komatsu T; Miura T; Joko K; Sunohara D; Mochidome T; Kasai T; Ikeda U
Intern Med; 2021 Sep; 60(17):2741-2748. PubMed ID: 33776008
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes.
Bando H; Taneda S; Manda N
JMA J; 2021 Apr; 4(2):135-140. PubMed ID: 33997447
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S;
J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
Katakura Y; Shimoda M; Ohnishi M; Kusano T; Dan K; Isobe H; Wamata R; Iwamoto Y; Fushimi Y; Sanada J; Obata A; Kimura T; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
Nutr Metab Cardiovasc Dis; 2023 Jul; 33(7):1444-1452. PubMed ID: 37246074
[TBL] [Abstract][Full Text] [Related]
12. Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia.
Hida Y; Imamura T; Kinugawa K
J Clin Med; 2023 Nov; 12(21):. PubMed ID: 37959379
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study.
Nakamura A; Kagaya Y; Saito H; Kanazawa M; Sato K; Miura M; Kondo M; Endo H
J Atheroscler Thromb; 2023 May; 30(5):443-454. PubMed ID: 35768226
[TBL] [Abstract][Full Text] [Related]
15. A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.
Sairyo M; Kobayashi T; Masuda D; Kanno K; Zhu Y; Okada T; Koseki M; Ohama T; Nishida M; Sakata Y; Yamashita S
J Atheroscler Thromb; 2018 Feb; 25(2):142-152. PubMed ID: 28781340
[TBL] [Abstract][Full Text] [Related]
16. Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study.
Kito K; Nomoto H; Sakuma I; Nakamura A; Cho KY; Kameda H; Miya A; Omori K; Yanagiya S; Handa T; Taneda S; Takeuchi J; Nagai S; Yamashita K; Kurihara Y; Atsumi T; Miyoshi H;
Diabetes Res Clin Pract; 2022 Oct; 192():110091. PubMed ID: 36174777
[TBL] [Abstract][Full Text] [Related]
17. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
Yokote K; Yamashita S; Arai H; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
Cardiovasc Diabetol; 2021 May; 20(1):96. PubMed ID: 33947390
[TBL] [Abstract][Full Text] [Related]
18. Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes.
Hoshino T; Ishizuka K; Toi S; Seki M; Kitagawa K
J Atheroscler Thromb; 2022 Jul; 29(7):1020-1030. PubMed ID: 34248089
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized comparative study of the effect of pemafibrate add-on or double statin dose on small dense low-density lipoprotein-cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy.
Hirano T; Hayashi T; Sugita H; Tamasawa A; Goto S; Tomoyasu M; Yamamoto T; Ohara M; Terasaki M; Kushima H; Ito Y; Yamagishi SI; Mori Y
J Diabetes Investig; 2023 Dec; 14(12):1401-1411. PubMed ID: 37647503
[TBL] [Abstract][Full Text] [Related]
20. Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study.
Komiya I; Yamamoto A; Sunakawa S; Wakugami T
Lipids Health Dis; 2021 Feb; 20(1):17. PubMed ID: 33610176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
